Contract facts
UnrestrictedDeveloping In-007 as a Widely Deployable Inhaled Treatment Against Pathogens Utilizing Human ACE2 for Viral Attachment… is a federal Unrestricted award for Army Med Res Acq Activity held by Inhalon Biopharma, Inc. Estimated value $2.2M ($2.2M obligated). Current period of performance ends Dec 22, 2026. Last award drew 47 bidders. Place of performance: MORRISVILLE NC. Related solicitation HT942523SJWMR.
Developing in-007 as a widely deployable inhaled treatment against pathogens utilizing human ace2 for viral attachment and entry revised statement of work and principal investigator change. Latest action is a modification.
Recompete timing
PublicCurrent PoP ends Dec 22, 2026 (66 days remaining). Agencies typically plan 12–18 months ahead — at 2.2 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on HT942524C0076? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordInhalon Biopharma, Inc — $5.4M obligated across 2 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HT942524C0076?
HT942524C0076 (Developing in-007 as a widely deployable) is a Army Med Res Acq Activity award with a potential value of $2.2M, currently held by Inhalon Biopharma, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is HT9425-24-C-0076?
HT9425-24-C-0076 is the dashed form of PIID HT942524C0076 (Developing in-007 as a widely deployable), held by Inhalon Biopharma, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded HT942524C0076?
Army Med Res Acq Activity awarded HT942524C0076 to Inhalon Biopharma, Inc (potential $2.2M).
Who is the incumbent on HT942524C0076?
Inhalon Biopharma, Inc is the incumbent with $5.4M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Dec 22, 2026.
When does Inhalon Biopharma, Inc’s HT942524C0076 come up for recompete?
SCOUT tracks a period-of-performance end of Dec 22, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on HT942524C0076? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.